Cargando…

Matrix-metalloproteinase-2, -8 and -9 in serum and skin blister fluid in patients with severe sepsis

INTRODUCTION: Matrix metalloproteinases (MMPs) have various roles in inflammatory states. They seem to be able to modulate endothelial barriers and regulate the activity of chemokines and cytokines. The timely development of the levels during severe sepsis and thereafter have not been investigated....

Descripción completa

Detalles Bibliográficos
Autores principales: Gäddnäs, Fiia P, Sutinen, Meeri M, Koskela, Marjo, Tervahartiala, Taina, Sorsa, Timo, Salo, Tuula A, Laurila, Jouko J, Koivukangas, Vesa, Ala-Kokko, Tero I, Oikarinen, Aarne
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2010
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2887163/
https://www.ncbi.nlm.nih.gov/pubmed/20356362
http://dx.doi.org/10.1186/cc8938
_version_ 1782182518197321728
author Gäddnäs, Fiia P
Sutinen, Meeri M
Koskela, Marjo
Tervahartiala, Taina
Sorsa, Timo
Salo, Tuula A
Laurila, Jouko J
Koivukangas, Vesa
Ala-Kokko, Tero I
Oikarinen, Aarne
author_facet Gäddnäs, Fiia P
Sutinen, Meeri M
Koskela, Marjo
Tervahartiala, Taina
Sorsa, Timo
Salo, Tuula A
Laurila, Jouko J
Koivukangas, Vesa
Ala-Kokko, Tero I
Oikarinen, Aarne
author_sort Gäddnäs, Fiia P
collection PubMed
description INTRODUCTION: Matrix metalloproteinases (MMPs) have various roles in inflammatory states. They seem to be able to modulate endothelial barriers and regulate the activity of chemokines and cytokines. The timely development of the levels during severe sepsis and thereafter have not been investigated. In addition it was of interest to study alterations of MMP-levels in intact skin, as the skin is the largest barrier against external pathogens and MMPs have not been studied at organ level in human sepsis. The aim of this study was to investigate the timely development of serum and skin MMP-2, -8 and -9 levels in human severe sepsis and their association with disease severity and mortality. METHODS: Forty-four patients with severe sepsis and fifteen healthy controls were included in this prospective longitudinal study. The amounts of MMP-2, -8 and -9 were analyzed from serum at days 1, 4, 6, 8, and 10, and from skin suction blister fluid at days 1 and 5 from the beginning of severe sepsis. Additionally, samples from the survivors were obtained after three and six months. RESULTS: The levels of MMP-2 and -8 were up-regulated in severe sepsis in comparison to healthy controls in skin blister fluid and serum. Compared to the controls MMP-9 levels were lower in sepsis from the fourth day on in serum and both the first and fifth day in skin blister fluid. Active forms of MMP-2 and -9 were present only in severe sepsis. The non-survivors had higher pro- and active MMP-2 levels than the survivors in skin blister fluid samples. Furthermore, MMP-2 levels were more pronounced in blister fluid and serum samples in patients with more severe organ failures. In the survivors at 3 and 6 month follow-up the MMP levels had returned to normal. CONCLUSIONS: MMP-2 and -8 are elevated in serum and blister fluid in severe sepsis, implying that they may play a significant role in the pathogenesis of severe sepsis and organ dysfunctions. Active forms of MMP-2 and 9 were only present in patients with severe sepsis, and higher MMP-2 levels in skin blister and serum were associated with more severe organ dysfunctions.
format Text
id pubmed-2887163
institution National Center for Biotechnology Information
language English
publishDate 2010
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-28871632010-06-18 Matrix-metalloproteinase-2, -8 and -9 in serum and skin blister fluid in patients with severe sepsis Gäddnäs, Fiia P Sutinen, Meeri M Koskela, Marjo Tervahartiala, Taina Sorsa, Timo Salo, Tuula A Laurila, Jouko J Koivukangas, Vesa Ala-Kokko, Tero I Oikarinen, Aarne Crit Care Research INTRODUCTION: Matrix metalloproteinases (MMPs) have various roles in inflammatory states. They seem to be able to modulate endothelial barriers and regulate the activity of chemokines and cytokines. The timely development of the levels during severe sepsis and thereafter have not been investigated. In addition it was of interest to study alterations of MMP-levels in intact skin, as the skin is the largest barrier against external pathogens and MMPs have not been studied at organ level in human sepsis. The aim of this study was to investigate the timely development of serum and skin MMP-2, -8 and -9 levels in human severe sepsis and their association with disease severity and mortality. METHODS: Forty-four patients with severe sepsis and fifteen healthy controls were included in this prospective longitudinal study. The amounts of MMP-2, -8 and -9 were analyzed from serum at days 1, 4, 6, 8, and 10, and from skin suction blister fluid at days 1 and 5 from the beginning of severe sepsis. Additionally, samples from the survivors were obtained after three and six months. RESULTS: The levels of MMP-2 and -8 were up-regulated in severe sepsis in comparison to healthy controls in skin blister fluid and serum. Compared to the controls MMP-9 levels were lower in sepsis from the fourth day on in serum and both the first and fifth day in skin blister fluid. Active forms of MMP-2 and -9 were present only in severe sepsis. The non-survivors had higher pro- and active MMP-2 levels than the survivors in skin blister fluid samples. Furthermore, MMP-2 levels were more pronounced in blister fluid and serum samples in patients with more severe organ failures. In the survivors at 3 and 6 month follow-up the MMP levels had returned to normal. CONCLUSIONS: MMP-2 and -8 are elevated in serum and blister fluid in severe sepsis, implying that they may play a significant role in the pathogenesis of severe sepsis and organ dysfunctions. Active forms of MMP-2 and 9 were only present in patients with severe sepsis, and higher MMP-2 levels in skin blister and serum were associated with more severe organ dysfunctions. BioMed Central 2010 2010-03-31 /pmc/articles/PMC2887163/ /pubmed/20356362 http://dx.doi.org/10.1186/cc8938 Text en Copyright ©2010 Gäddnäs et al.; licensee Biomed Central, Ltd. http://creativecommons.org/licenses/by/2.0 This is an open access article distributed under the terms of the Creative Commons attribution license (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research
Gäddnäs, Fiia P
Sutinen, Meeri M
Koskela, Marjo
Tervahartiala, Taina
Sorsa, Timo
Salo, Tuula A
Laurila, Jouko J
Koivukangas, Vesa
Ala-Kokko, Tero I
Oikarinen, Aarne
Matrix-metalloproteinase-2, -8 and -9 in serum and skin blister fluid in patients with severe sepsis
title Matrix-metalloproteinase-2, -8 and -9 in serum and skin blister fluid in patients with severe sepsis
title_full Matrix-metalloproteinase-2, -8 and -9 in serum and skin blister fluid in patients with severe sepsis
title_fullStr Matrix-metalloproteinase-2, -8 and -9 in serum and skin blister fluid in patients with severe sepsis
title_full_unstemmed Matrix-metalloproteinase-2, -8 and -9 in serum and skin blister fluid in patients with severe sepsis
title_short Matrix-metalloproteinase-2, -8 and -9 in serum and skin blister fluid in patients with severe sepsis
title_sort matrix-metalloproteinase-2, -8 and -9 in serum and skin blister fluid in patients with severe sepsis
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2887163/
https://www.ncbi.nlm.nih.gov/pubmed/20356362
http://dx.doi.org/10.1186/cc8938
work_keys_str_mv AT gaddnasfiiap matrixmetalloproteinase28and9inserumandskinblisterfluidinpatientswithseveresepsis
AT sutinenmeerim matrixmetalloproteinase28and9inserumandskinblisterfluidinpatientswithseveresepsis
AT koskelamarjo matrixmetalloproteinase28and9inserumandskinblisterfluidinpatientswithseveresepsis
AT tervahartialataina matrixmetalloproteinase28and9inserumandskinblisterfluidinpatientswithseveresepsis
AT sorsatimo matrixmetalloproteinase28and9inserumandskinblisterfluidinpatientswithseveresepsis
AT salotuulaa matrixmetalloproteinase28and9inserumandskinblisterfluidinpatientswithseveresepsis
AT laurilajoukoj matrixmetalloproteinase28and9inserumandskinblisterfluidinpatientswithseveresepsis
AT koivukangasvesa matrixmetalloproteinase28and9inserumandskinblisterfluidinpatientswithseveresepsis
AT alakokkoteroi matrixmetalloproteinase28and9inserumandskinblisterfluidinpatientswithseveresepsis
AT oikarinenaarne matrixmetalloproteinase28and9inserumandskinblisterfluidinpatientswithseveresepsis